Neue Entwicklungen in Diagnostik und Therapie primärer Non-Hodgkin-Lymphome des zentralen Nervensystems
| Autor: | M Schabet, R Clemens, U Herrlinger, Johannes Dichgans, M Barnberg, Michael Weller |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Chemotherapy
education.field_of_study Pathology medicine.medical_specialty medicine.diagnostic_test business.industry medicine.medical_treatment Population General Medicine medicine.disease Lymphoma Non-Hodgkin's lymphoma Radiation therapy Psychiatry and Mental health Neurology Biopsy medicine Neurology (clinical) Neurosurgery education business Survival rate |
| Zdroj: | Der Nervenarzt. 68:298-308 |
| ISSN: | 1433-0407 0028-2804 |
| DOI: | 10.1007/s001150050128 |
| Popis: | Primary central nervous system lymphomas (PCNSLs) are increasing in frequency both in immunocompetent and immunodeficient individuals. The majority of PCNSLs are high grade B cell lymphomas. In AIDS patients most tumors contain EBV genome. PCNSLs usually present as intracerebral, often deep-seated lesions half of which are multilocular. Less frequent are diffuse periventricular, exclusively leptomeningeal, ocular or spinal spread. On imaging PCNSLs show as contrast-enhancing lesions with relatively little perifocal edema. CSF protein is usually elevated. Malignant cells are present in 20-30% of cases. Demonstration of a monoclonal B cell population by immunocytology or FACS analysis may also be diagnostic. Once PCNSL is suspected extensive systemic evaluation is not useful. Instead, (stereotactic) biopsy of brain lesion(s) should be performed. Prior to biopsy, corticosteroids should be withheld as they may obscure diagnosis. Symptomatic edema or increased intracranial pressure should therefore initially be treated with osmotherapeutics. All immunodeficient patients should receive empiric anti-toxoplasmosis therapy for about 14 days prior to biopsy. AIDS patients with PCNSL survive 3 to 5 months (median) after whole brain irradiation and usually do not benefit from chemotherapy. Immunocompetent patients have a median survival of 12 to 18 months after whole brain irradiation alone, but a median survival of 33 to 43 months after combined radiochemotherapy using cytostatic drugs which penetrate the blood-brain barrier. Based on these encouraging results current concepts aim to intensify chemotherapy and to reduce or delay radiotherapy in the treatment of immunocompetent patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink